FDA Approves Pfizer’s Ibrance in Men With Breast Cancer

The U.S. Food and Drug Administration (FDA) approved Pfizer’s supplemental New Drug Application (NDA) for Ibrance (palbociclib) in combination with an aromatase inhibitor or fulvestrant for men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.